Top

Published in:

01-04-2012 | Colorectal Cancer

Adverse Features on Rectal MRI Identify a High-risk Group that May Benefit from More Intensive Preoperative Staging and Treatment

Authors: Chris J. Hunter, MBChB, MRCS, Aurelie Garant, Té Vuong, MD, FRCPC, Giovanni Artho, MD, Robert Lisbona, MD, FRCPC, Paris Tekkis, BMedSci, BMBS, MD, FRCS, Muti Abulafi, MS, FRCS, Gina Brown, MBBS, MRCP, FRCR, MD

Published in: Annals of Surgical Oncology | Issue 4/2012

Abstract

Background

Magnetic resonance imaging (MRI) is highly accurate in local staging of rectal cancer. It can identify features known to be associated with increased risk of metastatic disease. We evaluated the incidence of synchronous metastatic disease on fludeoxyglucose–positron emission tomography/computed tomography (FDG-PET/CT) and contrast-enhanced multiple-row detector computed tomography (ceMDCT) in MRI-stratified high- and low-risk rectal cancers. The aim was to determine the incidence of synchronous metastatic disease according to MRI risk features.

Methods

A total of 236 patients with rectal cancer were recruited to a study evaluating FDG-PET/CT. All patients underwent MRI staging and were stratified into high and low risk (high risk: extramural venous invasion, extramural spread of >5 mm or T4, involved circumferential resection margin or intersphincteric plane involved for low rectal tumors). Confirmed metastases were those identified on FDG-PET/CT and ceMDCT.

Results

Imaging data were available for 230 (97.5%) of 236 patients. Incidence of confirmed distant metastases was significantly greater in the MRI high-risk group, with 28 (20.7%) of 135 (95% confidence interval [CI] 14.8–28.3), versus the low-risk group, with 4 (4.2%) of 95 (95% CI 1.7–10.3) (odds ratio 6.0, 95% CI 2.0–17.6, P < 0.001).

Conclusions

Adverse features found on rectal MRI identify patients at increased risk of synchronous metastatic disease. This group may benefit from additional preoperative investigation for synchronous metastases such as FDG-PET/CT or liver MRI and from alternative neoadjuvant chemotherapy regimens including induction chemotherapy.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRef

Scholefield JH. Guidelines for the management of colorectal cancer. 3rd ed. London: Association of Coloproctology of Great Britain and Ireland; 2007.

Valentini V, Aristei C, Glimelius B, et al. Multidisciplinary rectal cancer management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol. 2009;92:148–63.PubMedCrossRef

Smith NJ, Shihab O, Arnaout A, Swift RI, Brown G. MRI for detection of extramural vascular invasion in rectal cancer. AJR Am J Roentgenol. 2008;191:1517–22.PubMedCrossRef

Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg. 2003;90:355–64.PubMedCrossRef

MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243:132–9.CrossRef

Taylor FG, Quirke P, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg. 2011;253(4):711–9.PubMedCrossRef

Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol. 2006;24:668–74.PubMedCrossRef

Dewdney A, Cunningham D, Tabernero J, et al. EXPERT-C: a randomized phase II European multicenter trial of neoadjuvant chemotherapy (capecitabine/oxaliplatin) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined high-risk rectal cancer. Presented at Gastrointestinal Cancers Symposium, San Francisco, 2011.

10.

Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med. 1998;17:2635–50.PubMedCrossRef

11.

Aloia TA, Fahy BN. A decision analysis model predicts the optimal treatment pathway for patients with colorectal cancer and resectable synchronous liver metastases. Clin Colorectal Cancer. 2008;7:197–201.PubMedCrossRef

12.

Slupski M, Wlodarczyk Z, Jasinski M, Masztalerz M, Tujakowski J. Outcomes of simultaneous and delayed resections of synchronous colorectal liver metastases. Can J Surg. 2009;52:E241–4.PubMed

13.

Hillingso JG, Wille-Jorgensen P. Staged or simultaneous resection of synchronous liver metastases from colorectal cancer—a systematic review. Colorectal Dis. 2009;11:3–10.PubMedCrossRef

14.

Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006;93:872–8.PubMedCrossRef

15.

Brouquet A, Mortenson MM, Vauthey JN, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010;210:934–41.PubMedCrossRef

16.

Heriot AG, Hicks RJ, Drummond EG, et al. Does positron emission tomography change management in primary rectal cancer? A prospective assessment. Dis Colon Rectum. 2004;47:451–8.PubMedCrossRef

17.

Orlacchio A, Schillaci O, Fusco N, et al. Role of PET/CT in the detection of liver metastases from colorectal cancer. Radiol Med. 2009;114:571–85.PubMedCrossRef

18.

Kong G, Jackson C, Koh DM, et al. The use of ¹⁸F-FDG PET/CT in colorectal liver metastases—comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging. 2008;35:1323–9.PubMedCrossRef

19.

Reinhardt MJ, Wiethoelter N, Matthies A, et al. PET recognition of pulmonary metastases on PET/CT imaging: impact of attenuation-corrected and non-attenuation-corrected PET images. Eur J Nucl Med Mol Imaging. 2006;33:134–9.PubMedCrossRef

20.

Dukes CE, Bussey HJ. The spread of rectal cancer and its effect on prognosis. Br J Cancer. 1958;12:309–20.PubMedCrossRef

21.

Dukes C, Bussey HJ. Venous spread in rectal cancer. Proc R Soc Med. 1941;34:571–3.PubMed

22.

Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.PubMedCrossRef

23.

Grinnell RS. The grading and prognosis of carcinoma of the colon and rectum. Ann Surg. 1939;109:500–33.PubMedCrossRef

24.

Quirke P, Williams GT, Ectors N, Ensari A, Piard F, Nagtegaal I. The future of the TNM staging system in colorectal cancer: time for a debate? Lancet Oncol. 2007;8:651–7.PubMedCrossRef

25.

Galizia G, Orditura M, Ferraraccio F, et al. The lymph node ratio is a powerful prognostic factor of node-positive colon cancers undergoing potentially curative surgery. World J Surg. 2009;33:2704–13.PubMedCrossRef

26.

Kim JH, Beets GL, Kim MJ, Kessels AG, Beets-Tan RG. High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? Eur J Radiol. 2004;52:78–83.PubMedCrossRef

27.

Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:241–8.PubMedCrossRef

Title: Adverse Features on Rectal MRI Identify a High-risk Group that May Benefit from More Intensive Preoperative Staging and Treatment
Authors: Chris J. Hunter, MBChB, MRCS
Aurelie Garant
Té Vuong, MD, FRCPC
Giovanni Artho, MD
Robert Lisbona, MD, FRCPC
Paris Tekkis, BMedSci, BMBS, MD, FRCS
Muti Abulafi, MS, FRCS
Gina Brown, MBBS, MRCP, FRCR, MD
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 4/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-2036-1

At a glance: The STEP trials

Springer Medicine

Adverse Features on Rectal MRI Identify a High-risk Group that May Benefit from More Intensive Preoperative Staging and Treatment

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2012

Micrometastases in Sentinel Lymph Nodes: Not Getting Lost in Translation

High Serum Hyaluronic Acid and HBV Viral Load are Main Prognostic Factors of Local Recurrence after Complete Radiofrequency Ablation of Hepatitis B-Related Small Hepatocellular Carcinoma

Lobular Breast Cancer: Same Survival and Local Control Compared with Ductal Cancer, but Should Both Be Treated the Same Way? Analysis of an Institutional Database over a 10-Year Period

Robot-Assisted Transaxillary Thyroid Surgery in the United States: Is it Comparable to Open Thyroid Lobectomy?

Is Focused Minimally Invasive Parathyroidectomy Appropriate for Patients With Familial Primary Hyperparathyroidism?

Feasibility of Surgery After Systemic Treatment with the Humanized Recombinant Antibody Bevacizumab in Heavily Pretreated Patients with Advanced Epithelial Ovarian Cancer